Premium
Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib ® treatment
Author(s) -
Kernt Marcus,
Staehler Michael,
Stief Christian,
Kampik Anselm,
Neubauer Aljoscha S.
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1600-0420.2007.01014.x
Subject(s) - medicine , sorafenib , bevacizumab , choroidal neovascularization , macular degeneration , ophthalmology , visual acuity , neovascularization , maculopathy , retinopathy , surgery , angiogenesis , chemotherapy , hepatocellular carcinoma , diabetes mellitus , endocrinology
. Purpose: To report on the effect of oral nexavar (Sorafenib ® ) treatment in one patient with neovascular age‐related macular degeneration (AMD) and advanced renal cell cancer (RCC). Methods: After two intravitreal injections of bevacizumab (1.25 mg) for occult choroidal neovascularization (CNV) in AMD, the patient was started on oral Sorafenib ® (400 mg twice daily) treatment for RCC. Results: Visual acuity (VA) was 20/80 in the left eye and optical coherence tomography (OCT) demonstrated persistent central thickening to 251 µm after bevacizumab. After 6 weeks of oral Sorafenib ® treatment, VA had increased to 20/70 and a significant decrease in retinal thickness to 208 µm was observed on OCT. The patient remained stable during a further 3 months of follow‐up. Conclusions: Resolution of macular oedema and stabilization of VA under oral treatment with the multikinase inhibitor Sorafenib ® was observed. This observation warrants further investigation.